As CRISPR patent fight nears the end game, where are settlement talks?
Source: As CRISPR patent fight nears the end game, where are settlement talks?
T
hree years after the University of California and the Broad Institute began battling over key patents on CRISPR-Cas9 genome editing inventions, the fat lady is finally about to sing in this multimillion-dollar operatic battle.
The U.S. Court of Appeals for the Federal Circuit, which heard oral arguments in the case on Monday, is expected to rule within 90 days on whether the Broad can keep its foundational CRISPR patents, as the patent office ruled last year. (IP experts think the chances of the Supreme Court accepting the case, if the losing party tries that route, are comparable to those of the Baltimore Orioles winning the 2018 World Series.)
Published at Wed, 02 May 2018 08:45:26 +0000
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.